2024-06-05 23:35:22 ET
Summary
- Pfizer's stock is currently trading below pre-pandemic levels, despite the record-breaking year it had in 2023 for FDA approvals and the significant acquisition of Seagen.
- Weak sentiment is likely explained by the significant risk of two best-selling products losing their exclusivity in 2026.
- Intrinsic value calculations suggest that the stock is 75% undervalued, meaning that the biggest risk is likely factored in.
My thesis
Pfizer ( PFE ) was one of few pharmaceutical companies which were able to develop the COVID-19 vaccine within a short period, and I was very surprised to find out that the stock currently trades below pre-pandemic levels....
Read the full article on Seeking Alpha
For further details see:
Pfizer: Too Cheap To Miss Out